XTX Topco Ltd Buys Shares of 2,313 Cencora, Inc. (NYSE:COR)

XTX Topco Ltd purchased a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 2,313 shares of the company's stock, valued at approximately $521,000.

Other hedge funds have also recently modified their holdings of the company. Lake Street Advisors Group LLC grew its stake in shares of Cencora by 1.3% during the 3rd quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company's stock worth $769,000 after purchasing an additional 43 shares during the period. Financial Advocates Investment Management lifted its stake in shares of Cencora by 4.7% in the 2nd quarter. Financial Advocates Investment Management now owns 978 shares of the company's stock valued at $220,000 after purchasing an additional 44 shares during the last quarter. Venturi Wealth Management LLC lifted its holdings in shares of Cencora by 1.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company's stock worth $1,001,000 after acquiring an additional 46 shares during the last quarter. Prime Capital Investment Advisors LLC boosted its position in shares of Cencora by 1.2% during the third quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company's stock worth $848,000 after buying an additional 46 shares during the period. Finally, Checchi Capital Advisers LLC boosted its stake in shares of Cencora by 2.2% in the second quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company's stock valued at $499,000 after purchasing an additional 48 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Performance

Shares of NYSE:COR traded up $0.12 on Friday, reaching $232.24. The company's stock had a trading volume of 780,788 shares, compared to its average volume of 1,386,901. The stock's 50-day moving average is $238.36 and its two-hundred day moving average is $234.04. Cencora, Inc. has a 52-week low of $195.83 and a 52-week high of $253.27. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The stock has a market capitalization of $44.89 billion, a P/E ratio of 30.92, a PEG ratio of 1.54 and a beta of 0.45.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, November 15th. This is an increase from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.95%. Cencora's dividend payout ratio (DPR) is currently 29.29%.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the sale, the chairman now directly owns 306,752 shares in the company, valued at $74,283,064.32. The trade was a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 93,018 shares of company stock worth $22,478,942 in the last three months. Insiders own 15.80% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on COR shares. Wells Fargo & Company reduced their target price on shares of Cencora from $249.00 to $237.00 and set an "equal weight" rating on the stock in a report on Friday. StockNews.com lowered Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. Mizuho started coverage on Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price target for the company. Robert W. Baird boosted their target price on Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their price target on Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a report on Wednesday, August 21st. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $275.60.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.